PERINATOLOGIYA I PEDIATRIYA. 2014. 1(57):97-100; doi 10.15574/PP.2014.57.97

Problem of dyslipidemia correction in adolescents with arterial hypertension

Golovchenko N. N., Sulzhenko M. Yu., Andreeva L. V., Kuznetsova M. A.

GI «Lugansk State Medical University», Ukraine

Луганська обласна дитяча клінічна лікарня, м. Луганськ, Україна

Тhe aim of our study was to determine the lipid profile in adolescents with hypertension, accompanied by overweight (BMI) and obesity, as well as evaluation of the impact of drug «Bittner Cardio».

Methods. We observed 61 adolescents with hypertension and overweight and obesity in the age from 12 to 18 years. Lipid profile (LР) has been studied on the basis of determining the levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), very low density lipoproteins (VLDL), low-density lipoprotein LDL spectrophotometric method. All patients received standard treatment of hypertension. For comparative evaluation of the effectiveness of the correction DLP patients were divided into two groups: I — 31 patients receiving the drug «Bittner Cardio», II — 30 people being prescribed dietary recommendations (to eat foods high in polyunsaturated fatty acids).

Results. Before the treatment, the children of I and II group complained about overweight — 61 patients (100%), increased blood pressure — 100%, headache — 90.2±3.8%, dizziness — 47.5±6.4%, cardialgia — 44.3±6.4%, epistaxis — 13.1±4.3%, increased appetite — 32.8±6.0%. Excess body weight was recorded at 32.8±6.0% adolescent obesity in 67.2±6.0% of patients. After 2 weeks of treatment 56 (91.8%) children of I and II groups improved their health, reduced blood pressure, and positive dynamics of LР was found. As a result of the treatment there was a significant decline in LР patients of I group. The level of ТС in 2 weeks of therapy was significantly reduced, reaching rates (3.93±0.59 mmol/l (p<0.01)). The decrease in blood ТС was accomplished by reducing the concentration of cholesterol in structure of LDL (2.10±0.40 mmol/l) and VLDL (0.79±0.22 mmol/l (p<0.05)). TG levels decreased significantly and after 2 weeks there was 1.53±0.32 mmol/l, which corresponds to the normal range. It should also note a significant increase in HDL in the blood of patients in group I — 1.22±0.14 mmol/l (p<0.05). In Group II, the level of total cholesterol tended to increase, although it remained in the normal range (4.63±0.33 mmol/l). The content of cholesterol that plays a leading anti-atherogenic role in this group of patients has decreased — 0.93±0.16 mmol/l. After treatment, a significant decrease of blood pressure in group I and II. However, the most positive dynamics as systolic and diastolic blood pressure was observed in the first group.

Conclusions. Cardio drug Bittner has produced a hypocholesterolemic effect, and in combination with antihypertensive drugs enhanced the hypotensive effect, reducing the daily dose of basic drugs.

Key words: lipid spectrum of the blood, hypertension, adolescents, treatment, omega-3 fatty acid.

REFERENCES

1. Кардиология и ревматология детского возраста. Под ред. ГА Самсыгиной и проф. МЮ Щербаковой. М, ИД Медпрактика. 2005: 744.

2. Коренев НМ, Богмат ЛФ, Носова ЕМ и др. 2005. Лекции по кардиологии детского возраста. М, ИД Медпрактика: 536.

3. Механизмы формирования нарушений липидного спектра крови у подростков с артериальной гипертензией. 2011. Артер гипертензия 5(19): 38—44.

4. Плотникова ИВ. 2007. Маркеры метаболического синдрома у подростков с артериальной гипертензией. Педиатрия 86;3: 39—43.

5. Бойцов СА и др. 2009. Структура факторов риска поражения органов-мишеней и метаболических изменений у больных артериальной гипертензии в различных возрастных группах. Кардиология 4: 19—24.

6. Чернишов ВА, Єрмакович ІІ. 2011. Поліклінічний досвід застосування препарату Вабадин (симвастатин) в корекції дисліпідемії в пацієнтів із високим ризиком кардіоваскулярних ускладнень. Артер гипертензия 5(19): 23—29.